Product Detail

loading

Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

CAS No.171290-52-1, Futibatinib Intermediate

  • 171290-52-1

  • C10H10O2

  • 162.18

  • 1.06±0.1

  • 97% min (HPLC)

  • 107.3

  • Off-white solid

  • Cholangiocarcinoma

  • Futibatinib

  • 11/05/2039 (Futibatinib)

  • FGFR

  • N

  • 2023

  • ISO 9001;ISO 14001;ISO 45001

Availability:
Inquire

CAS No.171290-52-1, Futibatinib Intermediate

Supply Chain

The Supply Chain Status in China

As of August 19, 2024, there are 77 potential suppliers manufacturing Futibatinib intermediate 1-Ethynyl-3,5-dimethoxybenzene (CAS No. 171290-52-1), including 10 factories and 21 labs, among which:

- The 25th percentile has an average registered capital of 1 million CNY;

- The 50th percentile has an average registerd capital of 5 million CNY;

-  The 75th percentile has an average registered capital of 10 million CNY.


Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.


Usage and ROS Analysis


Structure of Futibatinib

Futibatinib Structure

Structure of Futibatinib


There are three distinct moieties of Futibatinib:

  1. a pyrrolidine

  2. a pyrazolo[3,4-d]pyrimidine

  3. 1-ethynyl-3,5-dimethoxybenzene


The Overall Synthesis Map of Futibatinib

Futibatinib ROS


From the above synthesis map, the three key moieties correspond to the following Futibatinib intermediates

  1. a pyrrolidine: CAS No. 109431-87-0

  2. a pyrazolo[3,4-d]pyrimidine: CAS No. 151266-23-8

  3. 1-ethynyl-3,5-dimethoxybenzene: CAS No. 171290-52-1


For this particular Futibatinib intermediate, 1-Ethynyl-3,5-dimethoxybenzene, CAS No. 171290-52-1, the terminal carbon-carbon triple bond is to be reacted with the iodine atom on the pyrazolo[3,4-d]pyrimidine moiety using Palladium catalyst and CuI.


References

1.
Cheng, G. Synthesis method of drug fobatinib for treating cholangiocarcinoma. (2023).
 
2.
Ito, S. et al. Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use. ACS Med. Chem. Lett. 14, 396–404 (2023).
 
3.
Lindquist, S. L. et al. Inhibition of alpha-synuclein toxicity. (2007).
 
4.
Sagara, T., Ito, S., Otsuki, S. & Sootome, H. 3,5-disubstituted alkynylbenzene compound and salt thereof. (2015).


Previous: 
Next: 
CAS No.171290-52-1 Futibatinib Intermediate 1-Ethynyl-3 5-dimethoxybenzene China Supply Chain